近年来，国产创新药在国际舞台上频频取得突破，其中一个重要标志是‘里程碑款’的持续兑现。所谓里程碑款，是指在药物研发或商业化过程中，达成特定研发、临床或销售目标后，由合作方（如跨国药企）向创新药企支付的阶段性付款。这一款项不仅体现了对药物研发进展的认可，也反映了国际市场对中国原研能力的信心。例如，百济神州、信达生物、恒瑞医药等国内领先药企，已与诺华、礼来、默沙东等全球制药巨头达成多项授权合作，协议中包含数亿美元甚至数十亿美元的潜在里程碑付款。随着其候选药物在海外临床试验推进顺利、获批上市或实现销售目标，这些里程碑款正逐步兑现，为国内企业带来可观的非销售性收入，同时增强其持续研发投入的能力。里程碑款的兑现，标志着中国创新药从‘跟跑’向‘并跑’乃至‘领跑’转变，也预示着中国生物医药产业正加速融入全球创新体系。未来，随着更多国产创新药走向世界，此类国际合作与资金回流有望成为常态，进一步推动中国医药产业高质量发展。
In recent years, domestically developed innovative drugs from China have achieved significant breakthroughs on the global stage, with a key indicator being the frequent realization of ‘milestone payments.’ Milestone payments refer to staged payments made by partners—typically multinational pharmaceutical companies—to Chinese innovator firms upon achieving specific R&D, clinical, or commercial targets. These payments not only validate the progress of drug development but also reflect growing international confidence in China’s original drug discovery capabilities.For instance, leading Chinese biopharma companies such as BeiGene, Innovent Biologics, and Hengrui Medicine have entered into multiple licensing agreements with global giants like Novartis, Eli Lilly, and Merck. These deals often include potential milestone payments totaling hundreds of millions—or even billions—of U.S. dollars. As their drug candidates advance successfully through overseas clinical trials, gain regulatory approval, or meet sales targets, these milestone payments are increasingly being realized, providing substantial non-sales revenue that bolsters further R&D investment.The fulfillment of these milestone payments signals a strategic shift for China’s innovative drug sector—from ‘catching up’ to ‘keeping pace’ and even ‘taking the lead’ globally. It also underscores the accelerating integration of China’s biopharmaceutical industry into the global innovation ecosystem. As more homegrown innovative drugs reach international markets, such collaborations and associated financial inflows are expected to become the norm, further driving high-quality growth in China’s pharmaceutical sector.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/21772.html